Loading...

Regulus Therapeutics

DB:7RG1
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7RG1
DB
$12M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Regulus Therapeutics has significant price volatility in the past 3 months.
7RG1 Share Price and Events
7 Day Returns
-2.2%
DB:7RG1
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-84.1%
DB:7RG1
-7.4%
DE Biotechs
-5.6%
DE Market
7RG1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Regulus Therapeutics (7RG1) -2.2% 4.5% 18.3% -84.1% -98.5% -98.4%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 7RG1 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 7RG1 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
7RG1
Industry
5yr Volatility vs Market
Related Companies

7RG1 Value

 Is Regulus Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Regulus Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Regulus Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Regulus Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.978.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Regulus Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Regulus Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7RG1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.59
NasdaqCM:RGLS Share Price ** NasdaqCM (2019-04-24) in USD $1.16
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Regulus Therapeutics.

DB:7RG1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:RGLS Share Price ÷ EPS (both in USD)

= 1.16 ÷ -5.59

-0.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Regulus Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Regulus Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Regulus Therapeutics's expected growth come at a high price?
Raw Data
DB:7RG1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
9.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Regulus Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Regulus Therapeutics's assets?
Raw Data
DB:7RG1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.66
NasdaqCM:RGLS Share Price * NasdaqCM (2019-04-24) in USD $1.16
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:7RG1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:RGLS Share Price ÷ Book Value per Share (both in USD)

= 1.16 ÷ -0.66

-1.75x

* Primary Listing of Regulus Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Regulus Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 7RG1’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Regulus Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Regulus Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Regulus Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7RG1 Future Performance

 How is Regulus Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Regulus Therapeutics expected to grow at an attractive rate?
  • Unable to compare Regulus Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Regulus Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Regulus Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:7RG1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7RG1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 9.9%
DB:7RG1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 43.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7RG1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7RG1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 -40
2022-12-31 5 -25 -33 2
2021-12-31 5 -22 -30 2
2020-12-31 5 -18 -26 2
2019-12-31 1 -15 -27 2
DB:7RG1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -43 -49
2018-09-30 0 -50 -55
2018-06-30 0 -51 -60
2018-03-31 0 -56 -68
2017-12-31 0 -59 -72
2017-09-30 0 -63 -77
2017-06-30 0 -67 -81
2017-03-31 1 -67 -81
2016-12-31 1 -57 -82
2016-09-30 12 -59 -69
2016-06-30 14 -55 -63
2016-03-31 17 -48 -62

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Regulus Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Regulus Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7RG1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Regulus Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7RG1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 -1.51 -0.31 -2.70 2.00
2021-12-31 -1.33 -0.28 -2.38 2.00
2020-12-31 -3.40 -0.47 -7.61 3.00
2019-12-31 -3.93 -2.09 -7.95 4.00
DB:7RG1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.59
2018-09-30 -6.28
2018-06-30 -7.16
2018-03-31 -9.26
2017-12-31 -11.47
2017-09-30 -14.90
2017-06-30 -18.38
2017-03-31 -18.30
2016-12-31 -18.59
2016-09-30 -15.72
2016-06-30 -14.29
2016-03-31 -14.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Regulus Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Regulus Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Regulus Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7RG1 Past Performance

  How has Regulus Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Regulus Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Regulus Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Regulus Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Regulus Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Regulus Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Regulus Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7RG1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.07 -48.71 12.88
2018-09-30 0.07 -54.59 14.39
2018-06-30 0.07 -60.15 14.12
2018-03-31 0.07 -67.91 14.15
2017-12-31 0.07 -71.91 13.33
2017-09-30 0.07 -77.48 14.86
2017-06-30 0.26 -81.17 16.96
2017-03-31 0.72 -80.65 17.25
2016-12-31 1.19 -81.84 18.39
2016-09-30 12.04 -69.04 19.04
2016-06-30 13.70 -62.52 21.74
2016-03-31 17.05 -62.47 20.59
2015-12-31 20.76 -55.75 19.13
2015-09-30 14.12 -70.69 16.98
2015-06-30 13.34 -67.49 12.01
2015-03-31 10.24 -58.43 12.45
2014-12-31 7.67 -56.68 11.53
2014-09-30 8.90 -36.44 10.14
2014-06-30 13.94 -28.81 9.49
2014-03-31 17.96 -24.18 8.26
2013-12-31 19.57 -18.67 7.43
2013-09-30 17.35 -23.62 7.48
2013-06-30 14.04 -27.14 6.66
2013-03-31 12.59 -22.39 5.92
2012-12-31 12.70 -17.41 4.93
2012-09-30 12.83 -12.55 3.77
2012-06-30 13.83 -7.91 3.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Regulus Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Regulus Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Regulus Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Regulus Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Regulus Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7RG1 Health

 How is Regulus Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Regulus Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Regulus Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Regulus Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Regulus Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Regulus Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Regulus Therapeutics Company Filings, last reported 3 months ago.

DB:7RG1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -5.85 16.58 13.94
2018-09-30 1.58 19.07 20.52
2018-06-30 10.43 19.89 32.86
2018-03-31 22.88 19.87 45.13
2017-12-31 35.22 19.86 60.07
2017-09-30 48.58 19.85 71.37
2017-06-30 20.00 19.83 40.09
2017-03-31 38.73 19.82 57.46
2016-12-31 56.08 19.80 76.11
2016-09-30 72.69 19.79 91.58
2016-06-30 88.45 19.79 107.54
2016-03-31 107.23 0.00 105.10
2015-12-31 124.08 0.00 114.06
2015-09-30 125.86 0.00 130.33
2015-06-30 132.63 0.00 139.37
2015-03-31 146.83 0.00 148.79
2014-12-31 132.01 23.40 159.74
2014-09-30 74.08 10.67 94.07
2014-06-30 82.08 12.45 103.50
2014-03-31 92.29 13.40 114.60
2013-12-31 93.46 11.28 114.01
2013-09-30 94.45 13.92 123.90
2013-06-30 49.32 14.59 82.72
2013-03-31 55.87 11.90 90.72
2012-12-31 62.09 10.13 98.10
2012-09-30 -8.46 17.56 30.89
2012-06-30 2.48 5.60 27.01
  • Regulus Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Regulus Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Regulus Therapeutics has less than a year of cash runway based on current free cash flow.
  • Regulus Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.1% each year.
X
Financial health checks
We assess Regulus Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Regulus Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7RG1 Dividends

 What is Regulus Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Regulus Therapeutics dividends.
If you bought €2,000 of Regulus Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Regulus Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Regulus Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7RG1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7RG1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Regulus Therapeutics has not reported any payouts.
  • Unable to verify if Regulus Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Regulus Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Regulus Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Regulus Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Regulus Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Regulus Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7RG1 Management

 What is the CEO of Regulus Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jay Hagan
COMPENSATION $1,922,494
AGE 49
TENURE AS CEO 1.9 years
CEO Bio

Mr. Joseph P. Hagan, also known as Jay, has been the Chief Executive Officer, President and Director of Regulus Therapeutics Inc. since May 4, 2017. Mr. Hagan has been a Director at Aurinia Pharmaceuticals Inc. since February 21, 2018. He served as the Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer of Regulus Therapeutics Inc. from its joining on January 4, 2016 to May 4, 2017. Mr. Hagan is the Founder of Access Bioventures. He served as a Consultant of Orexigen Therapeutics, Inc. from December 12, 2015 to December 11, 2016. He served as the Chief Business & Financial Officer of Orexigen Therapeutics, Inc. from February 2015 to December 11, 2015 and served as its Treasurer until December 11, 2015. He served as an Executive Vice President and Principal Accounting Officer at Orexigen Therapeutics, Inc., and also served as Acting Chief Financial Officer since March 2011 and Chief Business Officer from June 2011 to December 2015. Mr. Hagan served as Senior Vice President of Corporate Development, Strategy, Communications, & Technical Operations at Orexigen Therapeutics from May 2009 to June 2011. Prior to Orexigen, he worked at Amgen, from September 1998 to April 2008, where he served in various senior business development roles, including Founder, President and Managing Director of Amgen Ventures. He joined Amgen Ventures in 1998 and oversaw and directed the fund's investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. Mr. Hagan served as the Head/Director of Corporate Development at Amgen Inc. He has led a number of notable transactions including the acquisitions of Tularik and Immunex as well as the sale of the Novantrone business. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences, where he served as a Biochemical Engineer. He also served at Advanced Tissue Sciences. He has been a Director of Zosano Pharma Corporation since May 22, 2015 and Allozyne, Inc. since November 4, 2005. He serves as a Director of Avidia, Inc. Mr. Hagan served as a Director at Relypsa, Inc., REN Pharmaceuticals, Inc., Accelerator Corporation and Integrated Diagnostics Inc. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from University of California, San Diego.

CEO Compensation
  • Jay's compensation has been consistent with company performance over the past year.
  • Jay's remuneration is higher than average for companies of similar size in Germany.
Management Team

Jay Hagan

TITLE
President
COMPENSATION
$2M
AGE
49
TENURE
1.9 yrs

Dan Chevallard

TITLE
Chief Financial Officer
COMPENSATION
$581K
AGE
37
TENURE
1.9 yrs

Chris Aker

TITLE
VP of Legal Affairs & Corporate Secretary

Turner Jenkins

TITLE
Director & Head of Corporate Development
Board of Directors Tenure

Average tenure and age of the Regulus Therapeutics board of directors in years:

1.9
Average Tenure
60.5
Average Age
  • The average tenure for the Regulus Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Stelios Papadopoulos

TITLE
Chairman of the Board of Directors
COMPENSATION
$200K
AGE
70
TENURE
5.8 yrs

Jay Hagan

TITLE
President
COMPENSATION
$2M
AGE
49
TENURE
1.9 yrs

David Baltimore

TITLE
Chairman of the Scientific Advisory Board & Director
COMPENSATION
$139K
AGE
80

Bill Rastetter

TITLE
Director
COMPENSATION
$155K
AGE
70
TENURE
6 yrs

Kate Collier

TITLE
Director
AGE
49
TENURE
1 yrs

Markus Stoffel

TITLE
Member of the Scientific Advisory Board

Thomas Tuschl

TITLE
Member of the Scientific Advisory Board

Hugh Rosen

TITLE
Director
COMPENSATION
$131K
AGE
59
TENURE
2.8 yrs

Tim Wright

TITLE
Member of the Scientific Advisory Board
COMPENSATION
$1M
AGE
62
TENURE
0.1 yrs

Pascale Witz

TITLE
Director
COMPENSATION
$151K
AGE
51
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Jan 19 Buy Stelios Papadopoulos Individual 28. Dec 18 28. Dec 18 50,000 €0.95 €47,672
28. Dec 18 Buy Stelios Papadopoulos Individual 26. Dec 18 27. Dec 18 116,401 €0.91 €99,340
19. Nov 18 Buy Kathryn Collier Individual 16. Nov 18 16. Nov 18 7,100 €1.24 €8,779
19. Nov 18 Buy Stelios Papadopoulos Individual 15. Nov 18 16. Nov 18 500,000 €1.21 €596,774
X
Management checks
We assess Regulus Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Regulus Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7RG1 News

Simply Wall St News

7RG1 Company Info

Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Details
Name: Regulus Therapeutics Inc.
7RG1
Exchange: DB
Founded: 2007
$11,135,645
10,743,922
Website: http://www.regulusrx.com
Address: Regulus Therapeutics Inc.
10614 Science Center Drive,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM RGLS Common Stock Nasdaq Capital Market US USD 04. Oct 2012
DB 7RG1 Common Stock Deutsche Boerse AG DE EUR 04. Oct 2012
Number of employees
Current staff
Staff numbers
24
Regulus Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:25
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.